Skip to content
Screener

Ardelyx ARDX Other Income (Expense)

Other Income (Expense) at other companies

Amgen logo
AmgenAMGN
-$73M+81.5%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$11M-175%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
-$5.58M+25.6%
XER
Xeris Biopharma Holdings, Inc.XERS
-$36.27M-466%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$53.4M+700%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$119K-77.2%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$996.75M-23.4%
Enterprise value$1.16B-18.5%
P/S2.2×-1.2×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations(12,425)(14,395)(45,218)(50,744)
Interest expense(4,957)(4,356)(10,556)(8,547)
Non-cash interest expense related to the sale of future royalties(1,267)(2,219)(2,584)(4,290)
Other income, net2,0381,8924,1504,218
Loss before provision for income taxes(16,611)(19,078)(54,208)(59,363)
Provision for income taxes1101118860
Net loss$(16,721)$(19,079)$(54,326)$(60,223)
Net loss per share of common stock - basic and diluted$(0.07)$(0.08)$(0.22)$(0.25)

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's other income (expense)?
Ardelyx (ARDX) reported other income (expense) of $2.04M in Q2 2026.
How has Ardelyx's other income (expense) changed year-over-year?
Ardelyx's other income (expense) increased by 7.7% year-over-year, from $1.89M to $2.04M.
What is the long-term trend for Ardelyx's other income (expense)?
Over 4 years (2021 to 2025), Ardelyx's other income (expense) has grown at a 88.9% compound annual growth rate (CAGR), from $687K to $8.75M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Ardelyx's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude